相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia
J. Bu et al.
LEUKEMIA (2018)
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
Eduardo Mendez et al.
CLINICAL CANCER RESEARCH (2018)
Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine
Tamara B. Garcia et al.
LEUKEMIA RESEARCH (2018)
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Stefanie Goellner et al.
NATURE MEDICINE (2017)
Updates in immunotherapy for acute myeloid leukemia
Emily Nagler et al.
TRANSLATIONAL CANCER RESEARCH (2017)
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Brenton G. Mar et al.
BLOOD (2017)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Nicholas J. Short et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
H. Parker et al.
LEUKEMIA (2016)
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
Olga A. Guryanova et al.
NATURE MEDICINE (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Sophia X. Pfister et al.
CANCER CELL (2015)
AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
James B. Ford et al.
ONCOTARGET (2015)
Identification of functional cooperative mutations of SETD2 in human acute leukemia
Xiaofan Zhu et al.
NATURE GENETICS (2014)
Targeting the Wee1 Kinase for Treatment of Pediatric Down Syndrome Acute Myeloid Leukemia
J. Timothy Caldwell et al.
PEDIATRIC BLOOD & CANCER (2014)
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia
Brenton G. Mar et al.
NATURE COMMUNICATIONS (2014)
Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
Annemie A. Van Linden et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells
Yue Zhang et al.
BLOOD (2012)
RNAi screening of the kinome with cytarabine in leukemias
Raoul Tibes et al.
BLOOD (2012)
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia
C. C. Porter et al.
LEUKEMIA (2012)
Kinase-independent function of checkpoint kinase 1 (Chk1) in the replication of damaged DNA
Juliana Speroni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage
Z. Wu et al.
CELL DEATH AND DIFFERENTIATION (2011)
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Timothy J. Guzi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
M. Wunderlich et al.
LEUKEMIA (2010)
Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling
Ming Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1
M Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II
NJ Krogan et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice
FX Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
分享论文
